India, Nov. 10 -- After Eli Lilly, Novo Nordisk has teamed up with an Indian partner to market its weight-loss drug under a new brand name in the world's third most obese country.

The Danish drugmaker will sell Poviztra 2.4 mg semaglutide injection in India as a separate brand of its blockbuster weight-loss drug WeGovy. This will be marketed by Emcure Pharmaceuticals Ltd. "This partnership is part of Novo Nordisk India's efforts to ensure its innovative treatments reach a greater number of patients in India," according to an exchange filing.

Novo Nordisk launched WeGovy in India in June, three months after Eli Lilly introduced Mounjaro. WeGovy's 2.4 mg dose is priced at Rs.26,015 for a month's supply in India, while pricing for Poviztra...